The UK artificial intelligence company BenevolentAI Ltd has decided to merge with a special purpose acquisition company in order to get access to more funding for its portfolio of drug candidates, discovered through the use of AI and machine learning. The merger is with Odyssey Acquisition SA of Luxembourg which raised €300 million for the transaction in July. Odyssey will raise an additional €135 million to complete the merger.
